Company Overview and News
Vistra Energy Corp. (VST - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $19.68–$21.13 in the past one-month time frame, witnessed a sharp increase yesterday.
Chicago, IL – April 10, 2018 - Stocks in this week’s article Weight Watchers International, Inc. (WTW - Free Report) , Match Group, Inc. (MTCH - Free Report) , Dynegy Inc. and HFF, Inc. (HF - Free Report) .
When value or growth investing fails to fetch sustained profits, one should explore another time-tested winning strategy that simply bets on the frontrunner stocks. Translated, one of the most successful strategies today is to get in on momentum stocks at the right time.
U.S. private sector employers made robust job additions in March, per a Automatic Data Processing Inc. ("ADP") and Moody’s Analytics report dated Apr 4. In fact, data from the same proved that the negative market sentiment about U.S. tariffs imposed on steel and aluminum by President Trump was overblown. Also, the U.S. Labor Department’s report released on Mar 9 showed that the economy added 313,000 jobs in February 2018, exceeding the consensus estimate of 208,000.
DTE Energy Company (DTE - Free Report) unveils plans to double its electricity generation capacity from renewable resources of energy in the State of Michigan by 2022. The proposal is part of the company’s 2018 Renewable Energy Plan, which was submitted to the Michigan Public Service Commission on Mar 30. The plan is in sync with DTE Energy’s earlier announced initiative to lower carbon emissions. Notably, the company projects to achieve this goal by reducing carbon emissions from its power plants up to 30%, 45%, 75% and more than 80% by early 2020s, 2030, 2040, and 2050, respectively.
Eversource Energy (ES - Free Report) has gained 1.0% in the last ten days compared with its industry's gain of 0.1%. The company pursues organic growth as well as strategic acquisitions to expand its operations. It is currently focused on upgrading its distribution and utility transmission infrastructure. The company has plans to invest $10.8 billion in the 2018-2021 time period.
Dynegy Inc. (DYN - Free Report) hit a new 52-week high of $13.58 before closing the session a bit lower at $13.38 on Mar 9. Year to date, the stock has delivered an impressive return of about 79.4% compared with the S&P 500 index’s rally of 17.8%. Over the past 52 weeks, Dynegy’s shares have ranged from a low of $5.84 to a high of $13.58. Average volume of shares traded over the last three months is approximately 3.
Investors in Dynegy Inc. (DYN - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 16, 2018 $9.00 Callhad some of the highest implied volatility of all equity options today.
Power supplier Southern Company’s (SO - Free Report) subsidiary, Georgia Power’s customers are expected to gain from the federal Tax Reform Legislation passed in December 2017. The cutback in the federal corporate income tax rate to 21% from 35% is likely to result in a savings of $1.2 billion for the Georgia Power customers. The savings would take place over the next two years. Georgia Public Service Commission ("PSC") has also confirmed the benefits as part of the agreement with Georgia Power.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET